Adult ADHD Assessment in Australia: Diagnosis, Costs & Wait Times (2026)

The AADPA Clinical Practice Guideline estimates that ADHD affects 2-6% of Australian adults — roughly 400,000 to 1.2 million people. Deloitte Access Economics estimated 533,300 adults and 281,200 children/adolescents had ADHD in 2019, totalling approximately 814,500 Australians.

ADHD is not something you grow out of. While hyperactivity may decrease with age, inattention and executive function difficulties typically persist into adulthood. Research published in the Australian and New Zealand Journal of Psychiatry confirmed that ADHD persists into adulthood and is associated with significant disadvantage across employment, relationships, and health outcomes.

A critical gap in Australian data: There are no Australian adult prevalence studies using current DSM-5 criteria (which reduced the adult symptom threshold from 6 to 5 symptoms in 2013). The 2-6% range is extrapolated from international meta-analyses. The actual number of affected Australian adults may be higher than current estimates suggest.

ADHD medication dispensing in Australia has increased at an extraordinary rate. AIHW data tells the story:

In 2023-24, 4.6 million prescriptions were dispensed to approximately 600,000 patients (about 2% of the Australian population). 87% of prescriptions were for psychostimulant medications.

• Gender trends are dramatic:**
• Male rates doubled from 11 to 26 per 1,000 between 2018-19 and 2023-24
• Female rates increased fivefold from 4 to 19 per 1,000 in the same period
• By 2022-23, female rates surpassed male rates in the 18-24 and 25-44 age groups for the first time

It took 14 years (2004-2018) to go from 2 to 8 per 1,000, but only 5 years (2018-2023) to go from 8 to 22 per 1,000. This acceleration reflects growing awareness, reduced stigma, and improved access — not an increase in actual ADHD prevalence. The Australian Psychological Society confirms that actual hyperactive/inattentive behaviours in the population have not increased.

The 2023 Senate Community Affairs References Committee inquiry into ADHD was a watershed moment. The committee received 700 submissions and heard from 79 witnesses across three public hearings, producing a 284-page report.

• Key findings:**
• Waiting lists exceeded 12 months for private specialists; 6-18 months was typical
• Out-of-pocket costs around $1,500 for diagnosis were common
• Access barriers included location, cost, stigma, gender, and cultural/linguistic background
• Different prescribing regulations in each state create a "postcode lottery"
• Inability to access adequate care has "lifelong" impacts on health, self-esteem, relationships, education, employment, and financial status

The committee made 15 unanimous recommendations including a national ADHD framework, nationally consistent prescribing rules, MBS and PBS reviews, shared models of care, and a public health campaign.

The government response was widely criticised. Only 1 of 15 recommendations was adopted (expediting uniform prescribing rules), with 9 given "in principle" support and 5 merely "noted." AADPA called it a "missed opportunity for real change."

Approximately 80% of adults with ADHD have at least one comorbid mental health condition. Understanding this is critical because comorbidities complicate diagnosis (ADHD can be mistaken for anxiety or depression) and require integrated treatment.

A large Norwegian registry study of 40,103 adults with ADHD (Solberg et al., 2018, Acta Psychiatrica Scandinavica) found that anxiety, depression, bipolar disorder, and personality disorders are more common in women with ADHD, while schizophrenia and substance use disorders are more prevalent in men. This has implications for how ADHD is assessed and treated across genders.

The AADPA guideline specifically recommends screening for comorbidities during ADHD assessment and addressing them as part of a comprehensive treatment plan.

Undiagnosed and untreated ADHD has massive economic consequences. Deloitte Access Economics estimated the total cost at $20.42 billion annually (2019):

• $12.83 billion in financial costs
• $7.59 billion in reduced wellbeing (burden of disease)
• 81% of financial costs come from productivity losses ($10+ billion)
• Per person cost: approximately $25,000 AUD per year

• Workplace impact:**
• Workers with ADHD are 30% more likely to have chronic employment issues
• 60% more likely to be fired from a job
• 3x more likely to quit impulsively
• Adults with untreated ADHD lose an average of 22 days of productivity per year (WHO data)
• Only 60% of Australians with ADHD have disclosed to their employer

Early diagnosis and treatment is cost-effective — the return on investment for ADHD treatment is among the highest of any mental health intervention.

Our directory lists 1000 ADHD providers across Australia. Browse all ADHD providers or filter to find providers who specifically list Adults (18+) as a focus area.

• Key provider types for adult ADHD:
• Psychologist: 238 providers (avg initial fee: $714)
• Psychiatrist: 214 providers (avg initial fee: $438)
• GP: 287 providers (avg initial fee: $384)
• Paediatrician: 261 providers (avg initial fee: $355)

Not all providers who treat ADHD are equally experienced with adults. Look for providers who explicitly list adult ADHD as a specialisation, not just ADHD in general.

Getting assessed as an adult involves these steps:

• See your GP — ask for a referral to a psychiatrist or psychologist who assesses adult ADHD. A GP who bulk bills makes this step free.
• Get a Mental Health Treatment Plan if seeing a psychologist — this provides Medicare rebates for up to 10 sessions per year
• Attend the assessment — typically 1-3 hours, involving clinical interview, rating scales, and developmental history
• Receive your diagnosis — the clinician will explain their findings and discuss treatment options
• Begin treatment — medication, therapy, coaching, or a combination

Who can diagnose: Psychiatrists and psychologists can diagnose ADHD. Psychiatrists can also prescribe medication. In QLD and SA, trained GPs can now diagnose and prescribe. In NSW (from March 2026), trained GPs will be able to diagnose.

Wait times: 4-12 months for in-person psychiatrists, 2-8 weeks for telehealth, 1-4 weeks for GP assessment (where available). Read our detailed guides on assessment costs and wait times for more information.

ADHD affects driving through impaired attention, increased impulsivity, and difficulty maintaining focus on monotonous tasks. International research shows:

• Adults with ADHD have a 1.23-1.49x higher crash risk compared to non-ADHD drivers
• Medication significantly reduces this risk — males on ADHD medication had 38% lower crash risk, females 42% lower, compared to their unmedicated periods
• An estimated 22% of crashes in people with ADHD could have been avoided with consistent medication use

Australian regulations: ADHD medication use is not a barrier to holding a driver's licence. The Austroads Fitness to Drive standards (2022) require individualised assessment — there is no blanket restriction based on ADHD diagnosis. Stimulant medication taken as prescribed may reduce rather than increase driving risk.

Roadside drug testing: Australian roadside oral fluid tests screen for methamphetamine, MDMA, and THC (NSW and QLD also test for cocaine). They will not detect prescription ADHD medications (dexamfetamine, methylphenidate, lisdexamfetamine). Keeping a letter from your prescriber confirming your medication is advisable for any roadside interactions.